News Headlines

  1. Lotus Pharmaceutical Becomes Commercialization Partner For Formycon's Keytruda Biosimilar Candidate FYB206 Across Major Parts Of The Asia-Pacific Region 2/10/2026

    Formycon AG and Lotus Pharmaceutical (“Lotus”) today announced the conclusion of an exclusive license agreement for Formycon’s Keytruda (1) biosimilar candidate FYB206 (Pembrolizumab).

  2. Kincell Bio Announces Partnership With RegCell To Advance Treg Cell Therapies Into Clinical Trials For Autoimmune Diseases 2/10/2026

    Kincell Bio, a leading U.S. cell therapy contract development and manufacturing organization (CDMO), today announced a new collaboration with RegCell, a biotechnology company developing first‑in‑class immune tolerance platform based on epigenetically reprogrammed regulatory T cells (Tregs).

  3. Trenchant BioSystems And Invetech Group Sign LOI To Form Strategic Alliance To Develop Fully Automated CGT Manufacturing Solution 2/10/2026

    Trenchant BioSystems Inc., the CGT manufacturing platform developer for gene-modified cells, and Invetech, a global leader in solving complex manufacturing and product development challenges in the advanced therapies and diagnostics markets, today announce the signing of a non-binding Letter or Intent (“LOI”) to form a strategic alliance to kickstart the development of Trenchant BioSystems’ AutoCell automated cell and gene therapy manufacturing platform from semi-automated Alpha prototype to a fully-automated commercial product.

  4. AsymBio Establishes Integrated Technology Platforms Spanning The Full Biopharmaceutical Development Lifecycle 2/10/2026

    AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms spanning the full biopharmaceutical development lifecycle. Through its end-to-end service capabilities, the company provides streamlined, integrated workflows from early development to commercial manufacturing.

  5. Kashiv BioSciences And Intas Pharmaceuticals Sign An Exclusive Licensing And Supply Agreement For Complex Peptide Product In Europe, The UK & India 2/9/2026

    Kashiv BioSciences, LLC (“Kashiv”) a vertically integrated biopharmaceutical company, today announced that it has entered into an exclusive licensing and supply agreement with Intas Pharmaceuticals Ltd (“Intas”), a leading multinational pharmaceutical company.

  6. Quantoom Biosciences Appoints Soter Bio As Exclusive North America RNA CDMO For RUO And GMP Manufacturing 2/9/2026

    Quantoom Biosciences, a leader in integrated RNA-LNP manufacturing technologies, today announced Soter Bio as its exclusive RNA Contract Development and Manufacturing Organization (CDMO) for both Research Use Only (RUO) and GMP manufacturing across North America, including the United States, Canada, and Mexico.

  7. Lilly To Acquire Orna Therapeutics To Advance Cell Therapies 2/9/2026

    Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna.

  8. Fresenius Kabi And Phlow Corp. Announce First-Ever, End-To-End, U.S. Manufacturing Collaboration For Epinephrine Injection, USP 2/9/2026

    Fresenius Kabi and Phlow Corp. announced today a first-of-its-kind collaboration to onshore the manufacture of Epinephrine Injection, USP, an essential medicine long at risk of chronic shortage in the U.S. and widely used in hospitals nationwide.

  9. Innovent Announces Strategic Collaboration With Lilly To Develop New Medicines Globally In Oncology And Immunology 2/8/2026

    Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, autoimmune, cardiovascular and metabolic, ophthalmologic, and other major diseases, today announced a strategic collaboration with Eli Lilly and Company ("Lilly") to advance novel medicines in oncology and immunology.

  10. Eisai And Henlius Enter Into Exclusive Commercial License Agreement For Anti-PD-1 Antibody Serplulimab In Japan 2/5/2026

    Eisai Co., Ltd. ("Eisai") and Shanghai Henlius Biotech, Inc. ("Henlius") today announced the conclusion of an exclusive commercialization and co-exclusive development and manufacturing license agreement for the anti-PD-1 antibody serplulimab (generic name; marketed as Hetronifly® in the EU) in Japan.